Pilot study: CD40L concentration during ECLS for analysis of platelet function

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

DRKS

Registry ID

DRKS00028899

Enrollment

Registered

2022-07-26

Start date

2022-10-01

Completion date

Unknown

Last updated

2025-04-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Reduced platelet function during ECLS/ECMO

Interventions

Group 1: Blood samples are drawn from ECLS (extracorporeal lilfe support) patients.

Eligibility

Sex/Gender

All

Age

18 Years to 80 Years

Inclusion criteria

Inclusion criteria: ECLS support

Exclusion criteria

Exclusion criteria: • Additional mechanical circulatory support (CPB, IABP, VAD); Impella are allowed • Heparin-induced thrombocytopenia Typ II • less than two measurements possible • participation is medically not possible • termination of the whole study

Design outcomes

Primary

Measure	Time frame
Concetration of sCD40L and release capacity of CD40L	—

Secondary

Measure	Time frame
Thrombopoetin Erythropoetin	—

Countries

Germany

Contacts

Public ContactDaniel Rother

Hochschule Furtwangen

daniel.rother@hs-furtwangen.de+49 15120107864

Outcome results

None listed

Source: DRKS (via WHO ICTRP) · Data processed: Feb 4, 2026